Description:
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a
CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced
solid tumors (Phase 1) and subjects with relapsed/recurrent GBM (Phase 2). The study is
designed to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of
USL311 alone and in combination with lomustine.
Title
- Brief Title: Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
- Official Title: A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)
Clinical Trial IDs
- ORG STUDY ID:
P311-201
- NCT ID:
NCT02765165
Conditions
- Solid Tumors (Phase 1)
- Relapsed/Recurrent GBM (Phase 2)
Interventions
Drug | Synonyms | Arms |
---|
USL311 | | Dose-Escalation USL311, Solid Tumor, Part 1a |
USL311 | | Dose-Escalation USL311, Solid Tumor, Part 1b |
USL311 | | Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2 |
Lomustine | | Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2 |
Purpose
This is a multicenter, open-label, Phase 1/2, dose-escalation and dose expansion study of a
CXCR4 inhibitor, USL311, alone and in combination with lomustine in subjects with advanced
solid tumors (Phase 1) and subjects with relapsed/recurrent GBM (Phase 2). The study is
designed to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of
USL311 alone and in combination with lomustine.
Trial Arms
Name | Type | Description | Interventions |
---|
Dose-Escalation USL311, Solid Tumor, Part 1a | Experimental | USL311, intravenous, once per week, starting at 60 mg/m˄2 | |
Dose-Escalation USL311, Solid Tumor, Part 1b | Experimental | USL311, oral, daily, starting at 40 mg | |
Dose-Escalation USL311 with Lomustine, Solid Tumor, Part 2 | Experimental | USL311, oral, daily, starting at dose as determined in Part 1b, in combination with lomustine 90 mg/m˄2, oral, once every 6 weeks | |
Dose-Expansion, USL311, GBM, Part 3 | Experimental | USL311, oral, daily, starting at dose determined in Part 1b | |
Dose-Expansion, USL311 with Lomustine, GBM, Part 4 | Experimental | USL311, oral, daily, in combination with lomustine, oral, once every 6 weeks, at dose(s) as determined in part 2 | |
Eligibility Criteria
Inclusion Criteria:
All Subjects:
1. Provide signed and dated informed consent prior to study-specific screening procedures
2. ≥ 18 years old
3. Karnofsky performance status (KPS) ≥ 70
4. Must have adequate bone marrow and renal/hepatic function within protocol specified
limits
5. Disease-free period of > 2 years from any other previous malignancies, excluding
curatively treated basal cell carcinoma, squamous cell carcinoma of the skin, or
carcinoma in situ of the cervix. Subjects with prostate cancer Stage 1 that do not
require treatment may also be included
6. Women and men must use protocol approved methods of contraception
7. Must be able and willing to comply with the study visit schedule and study procedures
8. Must be able to take oral medications
9. Must have available archived tumor tissue and willing and able to provide consent for
study access to such tissue
10. For subjects with a history of seizures, must be adequately controlled on a stable
regimen of anti-epileptic drugs
For Phase 1 Subjects Only:
11. Histologically or cytologically documented diagnosis of solid tumor for which no
standard therapy is recognized or have failed or intolerant to the standard-of-care
treatment
12. Inoperable metastatic or locally advanced, unresectable disease
13. Subjects may have either evaluable or measurable disease
14. Subjects with treated (surgically excised or irradiated) and stable brain metastases
are eligible as long as the subject has adequately recovered from treatment and the
treatment was ≥ 28 days prior to initiation of study drug(s) and baseline brain
computed tomography (CT) with contrast or magnetic resonance imaging (MRI) ≤ 14 days
of initiation of study drug is negative for new brain metastases
For Phase 2 Subjects Only:
15. Histologically confirmed diagnosis of GBM
16. Subjects must have documented recurrence after first-line treatment
17. Prior first-line treatment must have included radiation and temozolomide
18. Subject is suitable for re-resection, per Investigator discretion, as a component of
their clinical care
19. No more than one prior resection (Note: biopsy does not count as prior resection)
Exclusion Criteria:
All Subjects
1. Subjects who have had recent systemic anticancer therapies, interventional device
treatment and/or radiotherapy either within 14 days prior to first dose of study
drug(s) or have not recovered (to grade ≤ 1) from all clinically significant
toxicities related to prior therapies
2. Subjects who have had any major surgery (not including re-resection surgery required
in Phase 2) within 28 days prior to first dose of study drug(s), or minor surgery
within 14 days prior to first day of study drug(s)
3. Subjects taking any strong cytochrome P450 3A4 inducers within 14 days prior to the
first dose of study drug(s)
4. Subjects taking any strong cytochrome P450 3A4 inhibitors within 14 days prior to the
first dose of study drug(s)
5. Subjects taking any agents with moderate to high risk to prolong QT corrected (QTc)
interval or to cause Torsades de Pointes within 14 days prior to the first dose of
study drug(s)
6. Subjects who have been treated with an investigational agent or investigational
interventional device within 21 days prior to the first dose of study drug(s)
7. Subject is growth factor dependent or transfusion dependent, or has received growth
factor support or transfusion support within 14 days prior to the first dose of study
drug(s)
8. History of significant cardiac disease
9. Status epilepticus within 1 year prior to the first dose of study drug(s)
10. Pregnant or breastfeeding
11. Any other significant co-morbid conditions that in the opinion of the Investigator
would impair study participation or cooperation
For Phase 1 Subjects Only:
12. Lymphoma as primary cancer
For Phase 2 Subjects Only:
13. Unable or unwilling to consent to the provision of resected tissue after surgery
14. Prior treatment with plerixafor or another CXCR4 inhibitor
15. Prior treatment with bevacizumab
16. Prior treatment with lomustine and/or carmustine
For All Cohorts Receiving Oral USL311:
17. Any active medical condition or previous major abdominal surgery or procedure that
might, in the investigator's opinion, have a significant effect on USL311 absorption
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Phase 1: Maximum Tolerated Dose (MTD) |
Time Frame: | Assessed weekly during treatment period. Median duration of exposure was 5.14 (range 2.1-17.3) weeks. |
Safety Issue: | |
Description: | The MTD was defined as the highest safe dose (mg/m^2) administered where safe is defined by having at least a 50% probability that the dose limiting toxicity (DLT) rate is less than 33%, as determined by a modified continuous reassessment model. |
Secondary Outcome Measures
Measure: | Percentage Progression Free Survival (PFS) at 6 Months (PFS-6m) |
Time Frame: | Once every 6 weeks during treatment |
Safety Issue: | |
Description: | Percentage of subjects who were without progression at 6 months as assessed radiographically with response to treatment determined by Response Evaluation Criteria in Solid Tumors (RECIST) or Response Assessment in Neuro-Oncology (RANO) criteria. |
Measure: | Overall Survival (OS) |
Time Frame: | Weekly during treatment or every 12 weeks during follow-up |
Safety Issue: | |
Description: | Percentage of subjects alive five years after start of treatment. |
Measure: | Median Progression Free Survival (PFS) |
Time Frame: | Every 6 weeks during treatment |
Safety Issue: | |
Description: | Time after initiation of treatment before disease progression |
Measure: | Objective Response Rate (ORR%) |
Time Frame: | Every 6 weeks |
Safety Issue: | |
Description: | Percentage of patients whose disease decreased (Partial response) and/or disappears (Complete response) after initiation of treatment |
Measure: | Peak Concentration (Cmax) |
Time Frame: | Day 1 |
Safety Issue: | |
Description: | Peak USL311 concentration (Cmax) in plasma |
Measure: | Time to Peak Concentration (Tmax) |
Time Frame: | Day 1 |
Safety Issue: | |
Description: | Time to peak concentration of USL311 in plasma |
Measure: | Area Under the Concentration Versus Time Curve (AUC) |
Time Frame: | Day 1 |
Safety Issue: | |
Description: | Area under the curve versus time from time 0 to infinity for USL311 concentration in plasma |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Terminated |
Lead Sponsor: | Proximagen, LLC |
Trial Keywords
- Phase 1
- Phase 2
- Glioblastoma Multiforme
- Glioblastoma
- GBM
- Brain Tumor
- Brain Cancer
- Tumor
- Solid Tumor
- Tumour
- Lomustine
- CCNU
- CXCR4
- Phase 1 Clinical Trial
- Phase 2 Clinical Trial
Last Updated
July 23, 2021